OBJECT: Surgical intervention for appropriately selected patients with cervical spondylotic myelopathy (CSM) has demonstrated favorable outcomes. This study evaluates the cost-effectiveness of this type of surgery in terms of cost per quality-adjusted life year (QALY) gained. METHODS: As part of a larger prospective multicenter study, the direct costs of medical treatment for 70 patients undergoing surgery for CSM at a single institution in Canada were retrospectively obtained from the hospital expenses database and physician reimbursement data. Utilities were estimated on the entire sample of 278 subjects enrolled in the multicenter study using SF-6D-derived utilities from 12- and 24-month SF-36v2 follow-up information. Costs were analyzed from the payer perspective. A 10-year horizon with 3% discounting was applied to health-utilities estimates. Sensitivity analysis was performed by varying utility gain by 20%. RESULTS: The SF-6D utility gain was 0.0734 (95% CI 0.0557-0.0912, p < 0.01) at 12 months and remained unchanged at 24 months. The 10-year discounted QALY gain was 0.64. Direct costs of medical treatment were estimated at an average of CaD $21,066. The estimated cost-utility ratio was CaD $32,916 per QALY gained. The sensitivity analysis showed a range of CaD $27,326-$40,988 per QALY gained. These estimates are within the limits for medical procedures that have an acceptable cost-utility ratio. CONCLUSIONS: Surgical treatment for CSM is associated with significant improvement in health utilities as measured by the SF-6D. The direct cost of medical treatment per QALY gained places this form of treatment within the category deemed by payers to be cost-effective.
OBJECT: Surgical intervention for appropriately selected patients with cervical spondylotic myelopathy (CSM) has demonstrated favorable outcomes. This study evaluates the cost-effectiveness of this type of surgery in terms of cost per quality-adjusted life year (QALY) gained. METHODS: As part of a larger prospective multicenter study, the direct costs of medical treatment for 70 patients undergoing surgery for CSM at a single institution in Canada were retrospectively obtained from the hospital expenses database and physician reimbursement data. Utilities were estimated on the entire sample of 278 subjects enrolled in the multicenter study using SF-6D-derived utilities from 12- and 24-month SF-36v2 follow-up information. Costs were analyzed from the payer perspective. A 10-year horizon with 3% discounting was applied to health-utilities estimates. Sensitivity analysis was performed by varying utility gain by 20%. RESULTS: The SF-6D utility gain was 0.0734 (95% CI 0.0557-0.0912, p < 0.01) at 12 months and remained unchanged at 24 months. The 10-year discounted QALY gain was 0.64. Direct costs of medical treatment were estimated at an average of CaD $21,066. The estimated cost-utility ratio was CaD $32,916 per QALY gained. The sensitivity analysis showed a range of CaD $27,326-$40,988 per QALY gained. These estimates are within the limits for medical procedures that have an acceptable cost-utility ratio. CONCLUSIONS: Surgical treatment for CSM is associated with significant improvement in health utilities as measured by the SF-6D. The direct cost of medical treatment per QALY gained places this form of treatment within the category deemed by payers to be cost-effective.
Authors: Joseph E Tanenbaum; Daniel Lubelski; Benjamin P Rosenbaum; Edward C Benzel; Thomas E Mroz Journal: Clin Spine Surg Date: 2017-11 Impact factor: 1.876
Authors: Daniel Lubelski; Matthew D Alvin; Michael Silverstein; Nilgun Senol; Kalil G Abdullah; Edward C Benzel; Thomas E Mroz Journal: Eur Spine J Date: 2014-05-15 Impact factor: 3.134
Authors: Ruth Getachew; Sunghoon I Lee; Jon A Kimball; Andrew Y Yew; Derek S Lu; Charles H Li; Jordan H Garst; Nima Ghalehsari; Brian H Paak; Mehrdad Razaghy; Marie Espinal; Arsha Ostowari; Amir A Ghavamrezaii; Sahar Pourtaheri; Irene Wu; Majid Sarrafzadeh; Daniel C Lu Journal: J Neuroeng Rehabil Date: 2014-08-13 Impact factor: 4.262
Authors: Benjamin M Davies; M McHugh; A Elgheriani; Angelos G Kolias; Lindsay Tetreault; Peter J A Hutchinson; Michael G Fehlings; Mark R N Kotter Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: Michael G Fehlings; Lindsay A Tetreault; K Daniel Riew; James W Middleton; Bizhan Aarabi; Paul M Arnold; Darrel S Brodke; Anthony S Burns; Simon Carette; Robert Chen; Kazuhiro Chiba; Joseph R Dettori; Julio C Furlan; James S Harrop; Langston T Holly; Sukhvinder Kalsi-Ryan; Mark Kotter; Brian K Kwon; Allan R Martin; James Milligan; Hiroaki Nakashima; Narihito Nagoshi; John Rhee; Anoushka Singh; Andrea C Skelly; Sumeet Sodhi; Jefferson R Wilson; Albert Yee; Jeffrey C Wang Journal: Global Spine J Date: 2017-09-05